Drug Trial Radar · NCT07889492
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 5, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Edesa Biotech Inc.Industry
- Sponsor type
- Industry
- Collaborators
- JSS Medical Research Inc.
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe non-segmental vitiligo.. Vitiligo is a chronic autoimmune skin disorder characterized by the loss of skin pigmentation due to the destruction of melanocytes. EB06 is a fully human monoclonal antibody that binds and neutralizes CXCL10, a chemokine implicated in the trafficking of anti-melanocytic T-cells to the epidermis and in inducing cell death. Elevated levels of CXCL10 have been associated with both the initiation of the disease and the maintenance of vitiligo lesions. The study will evaluate the safety, tolerability, and efficacy of EB06 in adults with moderate to severe non-segmental vitiligo.
Conditions
- Non-Segmental Vitiligo (NSV)
Interventions
Placebo IVOther
Placebo IV
EB06Biological
EB06 IV loading 20 mg/kg followed by 10 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change from baseline in F-VASI at Week 28Time frame: 28 Weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Vida Clinical Research
Edmonton, Alberta, Canada · Not yet recruiting
Guelph Dermatology Research
Guelph, Ontario, Canada · Not yet recruiting
Clear Skin Dermatology
Newmarket, Ontario, Canada · Not yet recruiting
FACET Dermatology
Toronto, Ontario, Canada · Recruiting
CURAEX
Panama City, Panama · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.